FTC and NY sue Daraprim maker over access to samples
The Federal Trade Commission and state of New York have alleged that Vyera Pharmaceuticals broke federal antitrust laws by denying access to samples that competitors needed to replicate its infection-treating drug.
Subscribe to Global Competition Review
Subscribe and start reading now
Global Competition Review (GCR) is the complete source of news and analysis for competition practitioners. It keeps you up to speed with the issues and trends that matter, giving you the detail, and depth, you need to operate successfully.
Already have access? Login below
Copyright © Law Business ResearchCompany Number: 03281866 VAT: GB 160 7529 10